T. Friess

Blood · 2009–2010

A researcher in the Science corpus: 2 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Whom T. Friess trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. R. Nahta

Papers from T. Friess's perspective

Ordered by how strongly the researchers T. Friess trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets (Nature Medicine)
  2. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (Cancer Cell)
  3. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (Cancer Cell)
  4. Untangling the ErbB signalling network (Nature reviews. Molecular cell biology)
  5. The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells (Cancer Research)
  6. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
  7. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. (Cancer Research)
  8. A Unified Approach to Simultaneous Rank Test Procedures in the Unbalanced One-way Layout
  9. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab (Nature)
  10. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. (Cancer Cell)

Their papers